STK38

Across TCGA pan-cancer cohorts, STK38 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK38 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher STK38 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK38 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and SARC are the cancer types where STK38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
UCEC	DFS	Median	II,III,IV	1.000	0.440	.023	16	view →
SARC	DFS	Median	All	0.098	0.611	.006	6	view →
COAD	OS	Median	All	0.113	0.806	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STK38–BLCA (OS)

Open the BLCA breakdown →